课题基金 / 基金详情

Anticancer Agents--Structure and Synthesis

Anticancer Agents--Structure and Synthesis
抗癌剂--结构与合成
批准号:
7226313
负责人:
Amos B Smith
金额:
$24.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1976
资助国家:
美国
项目状态:
已结题
起止时间:
1976-06-30 至 2009-03-31
关键词:
3-hydroxybutanalAcademiaAccountingAchievementAcidsAlkenesAllyAnsamycin Antineoplastic AntibioticAntineoplastic AgentsArchitectureAreaArizonaAttentionBinding SitesBiologicalBiological AssayBiological FactorsCancer cell lineCell LineChemicalsChemotherapy-Oncologic ProcedureClassClinicalClinical TrialsCollaborationsComplexConditionCytolysisDNA Sequence RearrangementDataDevelopmentDimerizationElementsEpoxy CompoundsEvaluationEventExperimental DesignsFacility Construction Funding CategoryFamilyFutureGenerationsGlycosidesGoalsGrantGuanosine MonophosphateHalichondrin BHandHumanIndustryInstitutesInvestigationIsomerismLaboratoriesLaboratory AnimalsLearningLettersLibrariesLicensingMacrolidesMarinesMedicalMedical centerMedicineMethodsModelingMolecularMolecular ConformationMolecular Mechanisms of ActionMolecular ProbesMulti-Drug ResistanceNational Cancer InstituteOpticsOxazolesPaclitaxelPaperParentsPennsylvaniaPharmacologic SubstancePhasePhase I Clinical TrialsPhyllanthosidePositioning AttributePropertyProteinsProtocols documentationPublicationsRadiolabeledRangeReactionRelative (related person)ReportingResearchResearch InstituteRifabutinRiskRouteSchemeSeminalSeriesSolutionsSourceStructureStructure-Activity RelationshipStudy SectionStudy modelsTimeTreatment ProtocolsTubulinTumor PromotersUnited States National Institutes of HealthUniversitiesWeekWorkalkyl groupanaloganticancer researchantineoplastic antibioticsantitumor agentapicularen Abasecallystatin Acalyculincalyculin Acalyculin Bchloroacetatecollegecylindrocyclophane Acylindrocyclophane Fcytotoxicitydactylolidedesigndienediscodermolidedithianeimprovedinnovationinterestirciniastatin Airciniastatin Blituarine Alituarine Blituarine Cmacrolactin Amembermilligramnovelnovel strategiespeloruside Aphorboxazole Aphorboxazole Bpre-clinicalpressureprofessorprogramsquadroneradiotracerreceptor bindingresearch clinical testingsalicylihalamide Ascaffoldsizesolid statesoundstereochemistrystubomycinthiazinotrienomycin Etrienomycin Atrienomycin Eultra high pressurezampanolide

项目摘要

项目成果

Amos B Smith的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This research program (CA-19033), now in the twenty-eighth year, embodies our long-term commitment to the complete structural characterization and efficient, enantioselective synthesis of architecturally challenging anticancer agents. The principle goals for the 29-31 years can be divided into two major thrusts. In the (+)-phorboxazole area, we will: (A) deliver a minimum of one gram of (+)-phorboxazole A employing our now effective second-generation route, in order to make this important agent available for pre-clinical evaluation; (B) exploit the advanced phorboxazole intermediates for a detailed structure-activity study; (C) design and synthesize, guided by the structural activity results, less complex analogs; and (D) prepare chloroacetate, fluorescent, and radiolabeled photoaffinity analogs to define the protein receptor(s), binding site(s), and molecular mechanism(s) of action of this important antitumor agent. In the area of new target molecule/analog synthesis, we will: (E) complete our synthetic strategy for peloruside A; (F) design and synthesize, based on modeling studies, a series of (+)-peloruside A analogs to define the mode of action and binding site(s) of this new tubulin stabilizing antitumor agent; (G) complete the total synthesis of lituarines A, B and C, exploiting a non-aldol paradigm for the construction of polyketide structural units; and (H) initiate a new program directed at the total synthesis of the remarkably potent antitumor agents, (+)-irciniastatin A and B. In each case, the ultimate goal will be to deliver sufficient synthetic material for future biological study. In the area of new reactions/synthetic methods, the specific goals include: (I) develop and explore the scope of the non-aldol tactic to access diverse polyketide fragments of importance to complex molecule synthesis; and (J) demonstrate the utility of the non-aldol tactic for the ready construction of focused libraries based on known natural product scaffolds of biological interest. Beyond these specific synthetic objectives, a general, long-range goal of this program is the identification of the molecular architecture responsible for biological activity. Thus, as we develop an approach to each target structure, we will also prepare model compounds designed to permit the elucidation of structure-activity relationships.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dictyostatin and related prodrugs as candidates for tauopathy treatment
  • 批准号:
    8821175
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2014
  • 负责人:
    Amos B Smith
  • 依托单位:
Synthesis of Bioactive Natural Products
  • 批准号:
    8008963
  • 项目类别:
  • 资助金额:
    $9.9万
  • 财政年份:
    2010
  • 负责人:
    Amos B Smith
  • 依托单位:
Alzhelmer's Disease Drug Development Program
  • 批准号:
    7676129
  • 项目类别:
  • 资助金额:
    $64.07万
  • 财政年份:
    2008
  • 负责人:
    Amos B Smith
  • 依托单位:
Alzhelmer's Disease Drug Development Program
  • 批准号:
    7525036
  • 项目类别:
  • 资助金额:
    $63.32万
  • 财政年份:
    2008
  • 负责人:
    Amos B Smith
  • 依托单位:
海外基金